Translational Molecular Imaging
Group Leader:
Prof David Lewis
Translating Imaging Science into Impact — the TMI Facility develops and deploys cutting-edge PET/MRI technologies, radiotracers, and analytics for cancer research and clinical translation. The Translational Molecular Imaging (TMI) Facility, led by Prof David Lewis, advances novel imaging technologies and serves as a shared resource for researchers across the CRUK Scotland Institute and Scotland Cancer Centre. As a hub for emerging imaging science, TMI connects preclinical discovery to clinical implementation. We specialise in novel PET probes, imageable transgenic models, multi-tracer workflows, and AI-enabled analytics integrated with spatial-omics. TMI supports everything from facilitated scanning to fully collaborative development of imaging agents and pharmacodynamic biomarkers. Our work targets metabolic heterogeneity and systemic metabolism (e.g., cachexia), delivering non-invasive biomarkers for classification, patient stratification, therapy guidance, and clinical translation.

Recent Publications

Lab Members
Recent Publications
2024
Hesketh, R. L.; Lewis, D. Y.; Brindle, K. M. (2024). Optimisation of Animal Handling and Timing of 2-deoxy-2-[18F] fluoro-D-glucose PET Tumour Imaging in Mice. Molecular Imaging and Biology, 26 (6), 965-976.
2023
Villar, V. H., Allega, M. F., Deshmukh, R., Ackermann, T., Nakasone, M. A.; Vande Voorde, J., Drake, T. M., Oetjen, J. Bloom, A., Nixon, C. (2023). Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. Nature Chemical Biology. 19 (3), 292-300.
Lewis, D. Y. (2023). Multiplexing Autoradiography. Positron Emission Tomography: Methods and Protocols. 423-439.
Brown, G., Solovyev, D., Lewis, D. (2023). Radiosynthesis and analysis of (S)-4-(3-[18F] fluoropropyl)-L-glutamic acid. Nuclear Medicine and Biology. 126, S73-S74.
2022
Soloviev, D., Dzien, P., Mackintosh, A., Malviya, G., Brown, G., Lewis, D. (2022). High molar activity [18F] tetrafluoroborate synthesis for sodium iodide symporter imaging by PET. EJNMMI Radiopharmacy and Chemistry. 7 (1), 32.
2020
Malviya, G., Patel, R., Salji, M., Martinez, R. S., Repiscak, P., Mui, E., Champion, S., Mrowinska, A., Johnson, E., AlRasheedi, M. (2020). 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy. EJNMMI Research. 10 (1), 143.
2019
Witney, T. H., Lewis, D. Y. (2019). Imaging cancer metabolism with positron emission tomography (PET). Cancer Metabolism: Methods and Protocols. 29-44.
2018
Zmuda, F., Blair, A., Liuzzi, M. C., Malviya, G., Chalmers, A. J., Lewis, D., Sutherland, A., Pimlott, S. L. (2018). An 18F-labeled poly (ADP-ribose) polymerase positron emission tomography imaging agent. Journal of Medicinal Chemistry. 61 (9), 4103-4114.
PET Research Development Manager
Una Goncin
I leverage extensive expertise in project management, multimodal imaging, clinical trial management, and communications to drive the growth and impact of PET research in Glasgow. In my role, I lead the development, implementation, and oversight of PET imaging strategy, ensuring operational excellence, resource optimisation, and regulatory My role includes building collaborations, supporting and securing research funding, and creating opportunities for translational success. I lead marketing and outreach initiatives to raise the profile of PET research and ensure its long-term sustainability.
Senior Scientific Officer
Carol McMenemy
Head of Radiochemistry
Dmitry Soloviev
As Head of Radiochemistry, I lead radiochemistry efforts supporting PET imaging studies across Scotland, driving innovation in molecular imaging. My team has extensive expertise in radiopharmaceutical development, short-lived positron-emitting radionuclides, and advanced radiolabelling techniques. We specialize in radiolabelling metabolites to uncover cancer biochemistry and the interplay between disease biology and imaging.
By advancing preclinical and clinical PET studies, we help researchers translate discoveries into real-world impact.


